JP2002500202A - 免疫優位部位の生成のための色素性網膜上皮細胞の使用 - Google Patents

免疫優位部位の生成のための色素性網膜上皮細胞の使用

Info

Publication number
JP2002500202A
JP2002500202A JP2000527281A JP2000527281A JP2002500202A JP 2002500202 A JP2002500202 A JP 2002500202A JP 2000527281 A JP2000527281 A JP 2000527281A JP 2000527281 A JP2000527281 A JP 2000527281A JP 2002500202 A JP2002500202 A JP 2002500202A
Authority
JP
Japan
Prior art keywords
cells
rpe
site
mammal
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000527281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002500202A5 (enExample
Inventor
リチャード シー． アレン，
マイケル エル． コーンフェルドット，
ウイリアム アール． キドウェル，
Original Assignee
タイタン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タイタン ファーマシューティカルズ， インコーポレイテッド filed Critical タイタン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2002500202A publication Critical patent/JP2002500202A/ja
Publication of JP2002500202A5 publication Critical patent/JP2002500202A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
JP2000527281A 1998-01-02 1998-12-31 免疫優位部位の生成のための色素性網膜上皮細胞の使用 Pending JP2002500202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US241398A 1998-01-02 1998-01-02
US09/002,413 1998-01-02
PCT/US1998/027730 WO1999034834A1 (en) 1998-01-02 1998-12-31 Use of pigmented retinal epithelial cells for creation of an immune privilege site

Publications (2)

Publication Number Publication Date
JP2002500202A true JP2002500202A (ja) 2002-01-08
JP2002500202A5 JP2002500202A5 (enExample) 2006-01-05

Family

ID=21700636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000527281A Pending JP2002500202A (ja) 1998-01-02 1998-12-31 免疫優位部位の生成のための色素性網膜上皮細胞の使用

Country Status (8)

Country Link
US (1) US20060147437A1 (enExample)
EP (1) EP1044024A1 (enExample)
JP (1) JP2002500202A (enExample)
KR (1) KR20010033834A (enExample)
AU (1) AU759273B2 (enExample)
CA (1) CA2317115A1 (enExample)
NZ (1) NZ505459A (enExample)
WO (1) WO1999034834A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004243125A (ja) * 2003-02-11 2004-09-02 Ethicon Inc 哺乳動物細胞を接種した植え込み可能な医療デバイスおよび治療方法
JP2012148085A (ja) * 2004-01-23 2012-08-09 Advanced Cell Technology Inc 網膜変性疾患治療のための改良された様式
US9040038B2 (en) 2004-01-23 2015-05-26 Ocata Therapeutics, Inc. Modalities for the treatment of degenerative diseases of the retina
US10077424B2 (en) 2007-10-12 2018-09-18 Astellas Institute For Regenerative Medicine Methods of producing RPE cells and compositions of RPE cells
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115256B1 (en) 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
JP2002281964A (ja) * 2000-12-26 2002-10-02 Sanyo Chem Ind Ltd 細胞生産方法
WO2002066620A2 (de) * 2001-02-21 2002-08-29 Stefan Kochanek Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
WO2003092723A1 (de) * 2002-05-03 2003-11-13 Nikolai Rainov Verwendung von fasl zur behandlung von neurodegenerativen erkrankungen
EP1551956A4 (en) 2002-07-12 2006-12-27 Univ Washington METHOD AND SYSTEMS FOR THE EXTENDED IN VITRO CULTURE OF NEURONAL CELLS
IL287381B2 (en) * 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300436A (en) * 1991-03-13 1994-04-05 New York University Genetically modified tyrosine hydroxylase and uses thereof
JPH07503467A (ja) * 1992-01-23 1995-04-13 ニューヨーク ユニヴァーシティー 細胞を脳に移植する方法及びその治療使用
JPH09501303A (ja) * 1993-04-30 1997-02-10 フォトジェネシス インコーポレイテッド 網膜色素上皮移植

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
AU715177B2 (en) * 1994-04-13 2000-01-20 Research Corporation Technologies, Inc. Methods of treating disease using sertoli cells and allografts or xenografts
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300436A (en) * 1991-03-13 1994-04-05 New York University Genetically modified tyrosine hydroxylase and uses thereof
JPH07503467A (ja) * 1992-01-23 1995-04-13 ニューヨーク ユニヴァーシティー 細胞を脳に移植する方法及びその治療使用
JPH09501303A (ja) * 1993-04-30 1997-02-10 フォトジェネシス インコーポレイテッド 網膜色素上皮移植

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DUNAIEF J.L.: "RETROVIRAL GENE TRANSFER INTO RETINAL PIGMENT EPITHELIAL CELLS FOLLOWED 以下備考", HUMAN GENE THERAPY, vol. V6N9, JPN5001002541, 1 September 1995 (1995-09-01), pages 1225 - 1229, ISSN: 0001250307 *
GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (1997), VOL.235, P.103-110, JPN7009000831, ISSN: 0001250308 *
JORGENEEN A ET AL. HUMAN RETINAL PIGMENT EPITHELIAL CELLS INDUCE APOPTOSIS IN ACTIVATED T CELLS. INV, JPN6009006885, ISSN: 0001250306 *
SELAWRY HP. ET AL. SERTOLI CELL-ENRICHED FRACTIONS IN SUCCESSFUL ISLET CELL TRANSPLANTATION. CELL TR, JPN6009006881, ISSN: 0001250304 *
STREILEIN J. UNRAVELING IMMUNE PRIVILEGE. SCIENCE (1995), VOL.270, P.1158-1159, JPN6009006883, ISSN: 0001250305 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004243125A (ja) * 2003-02-11 2004-09-02 Ethicon Inc 哺乳動物細胞を接種した植え込み可能な医療デバイスおよび治療方法
JP2016195862A (ja) * 2004-01-23 2016-11-24 アステラス インスティテュート フォー リジェネレイティブ メディシン 網膜変性疾患治療のための改良された様式
US9650607B2 (en) 2004-01-23 2017-05-16 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
US9040770B2 (en) 2004-01-23 2015-05-26 Ocata Therapeutics, Inc. Modalities for the treatment of degenerative diseases of the retina
US9040038B2 (en) 2004-01-23 2015-05-26 Ocata Therapeutics, Inc. Modalities for the treatment of degenerative diseases of the retina
US9040039B2 (en) 2004-01-23 2015-05-26 Ocata Therapeutics, Inc. Modalities for the treatment of degenerative diseases of the retina
US9045732B2 (en) 2004-01-23 2015-06-02 Ocata Therapeutics, Inc. Modalities for the treatment of degenerative diseases of the retina
US9080150B2 (en) 2004-01-23 2015-07-14 Ocata Therapeutics, Inc. Modalities for the treatment of degenerative diseases of the retina
US9181524B2 (en) 2004-01-23 2015-11-10 Ocata Therapeutics, Inc. Modalities for the treatment of degenerative diseases of the retina
US9193950B2 (en) 2004-01-23 2015-11-24 Ocata Therapeutics, Inc. Modalities for the treatment of degenerative diseases of the retina
JP2012148085A (ja) * 2004-01-23 2012-08-09 Advanced Cell Technology Inc 網膜変性疾患治療のための改良された様式
JP2014079650A (ja) * 2004-01-23 2014-05-08 Advanced Cell Tech Inc 網膜変性疾患治療のための改良された様式
US9649340B2 (en) 2004-01-23 2017-05-16 Astellas Institute For Regenerative Medicine Methods for producing enriched populations of human retinal pigment epithelium cells
US9562217B2 (en) 2004-01-23 2017-02-07 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
US9730962B2 (en) 2004-01-23 2017-08-15 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
JP2018086274A (ja) * 2004-01-23 2018-06-07 アステラス インスティテュート フォー リジェネレイティブ メディシン 網膜変性疾患治療のための改良された様式
JP2022153630A (ja) * 2004-01-23 2022-10-12 アステラス インスティテュート フォー リジェネレイティブ メディシン 網膜変性疾患治療のための改良された様式
JP2020146575A (ja) * 2004-01-23 2020-09-17 アステラス インスティテュート フォー リジェネレイティブ メディシン 網膜変性疾患治療のための改良された様式
JP2019217356A (ja) * 2004-01-23 2019-12-26 アステラス インスティテュート フォー リジェネレイティブ メディシン 網膜変性疾患治療のための改良された様式
US10077424B2 (en) 2007-10-12 2018-09-18 Astellas Institute For Regenerative Medicine Methods of producing RPE cells and compositions of RPE cells
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
US11850261B2 (en) 2009-11-17 2023-12-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

Also Published As

Publication number Publication date
EP1044024A1 (en) 2000-10-18
AU759273B2 (en) 2003-04-10
KR20010033834A (ko) 2001-04-25
CA2317115A1 (en) 1999-07-15
AU2019199A (en) 1999-07-26
NZ505459A (en) 2003-07-25
WO1999034834A1 (en) 1999-07-15
US20060147437A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
US7115257B1 (en) ARPE-19 as a platform cell line for encapsulated cell-based delivery
JP4741189B2 (ja) 増殖した細胞系およびその使用方法
CA2113118C (en) Novel growth factor-responsive progenitor cells which can be proliferated in vitro
EP1261357B1 (en) Isolation and transplantation of retinal stem cells
AU759273B2 (en) Use of retinal pigment epithelial cells for creation of an immune privilege site
AU2006255183B2 (en) A cellular therapy for ocular degeneration
Sun et al. Retinal stem/progenitor properties of iris pigment epithelial cells
US20050031599A1 (en) Pharmaceuticals containing retinal stem cells
US20030032183A1 (en) Stem cell differentiation
Gospodarowicz et al. The coating of bovine and rabbit corneas denuded of their endothelium with bovine corneal endothelial cells
US20030125293A1 (en) Adipose tissue-derived stromal cells for the repair of corneal and intra-orbital defects and uses thereof
JPH06502406A (ja) 脳中への細胞の移植方法およびそのための治療的使用
Hu et al. Transplantation site affects the outcomes of adipose‐derived stem cell‐based therapy for retinal degeneration
CA2450650C (en) Encapsulated cell therapy
US20090269319A1 (en) ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
Oda et al. A simple method for the Schwann cell preparation from newborn rat sciatic nerves
MXPA00006546A (en) Use of pigmented retinal epithelial cells for creation of an immune privilege site
US12226452B2 (en) Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons
EP4176870A1 (en) Extracellular vesicles or composition thereof for use as a medicament, such as for the treatment of ocular surface disorders
WO2023110824A1 (en) Novel integrin associated protein (iap)
Mitrousis A Bioengineering Approach Towards Retina Regeneration
CA2399589A1 (en) Novel growth factor-responsive progenitor cells which can be proliferated in vitro
AU2002312125A1 (en) Stem cell differentiation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090722